ArticlePLOS global public health2026
Seeing the similarities: Applying a coherent lens to harmful products as drivers of suicide.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatal self-harm, more commonly referred to as suicide, is a serious public health problem affecting individuals and communities worldwide. Some products and services, such as paracetamol, bridges, and railways, are recognised as requiring regulatory or design interventions to prevent suicide. However, others with well-established associations with suicide, including alcohol, gambling products, pesticides, opioids and firearms, are often framed as safe when used appropriately, even in the absence of effective regulation. In such cases, responsibility for harm is shifted onto individuals rather than directed towards harmful products and the industries that produce them. This article aims to examine this divergence, asking why certain products are problematised while others with clear links to suicide are heavily promoted and widely accessible. It examines the structural and commercial factors that sustain these inconsistencies. In so doing, we argue that such diverging approaches to harmful products deserve more effective scrutiny and call for the consistent application of a prevention lens across all products linked to self-harm and fatal outcomes. Such an approach is essential to advancing global suicide prevention efforts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.